Opinion | April 17, 2026
Beyond beds and buildings: The quiet capital shift reshaping healthcare
The investment case for health technology in India is frequently overstated in one direction and understated in another
The investment case for health technology in India is frequently overstated in one direction and understated in another
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The new capital is expected to fund the company through 2029
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
